Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGFBPL1 CAR-T
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IGFBPL1 CAR-T is a peptide-centric chimeric antigen receptor (CAR) T-cell therapy being developed by MyriO Tx for the treatment of neuroblastoma and other pediatric cancers. The therapy is engineered to target Insulin-like Growth Factor Binding Protein-Like 1 (IGFBPL1), a protein that is presented as peptides on HLA-A*02:01 molecules on the surface of pediatric tumor cells. MyriO Tx utilizes its proprietary Retained Display (ReD) antibody discovery platform to generate highly specific single-chain variable fragment (scFv) binders against these peptide-MHC complexes. This approach allows the CAR-T cells to target intracellular antigens that are typically inaccessible to conventional CAR-T therapies. As of 2025, the program is in IND-enabling studies.
- Other names
- IGFBPL1 CAR-T (Pediatric)IGFBPL1-CAR-T-cell therapyIGFBPL-1-CAR-T-cell therapyIGFBPL 1-CAR-T-cell therapy
02
Targets
IGFBPL1 (Insulin-like growth factor-binding protein-like 1)
Beyond the preview
Go deeper on IGFBPL1 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGFBPL1 CAR-T.